Brief Report Open Access
Volume 5 | Issue 2 | DOI: https://doi.org/10.33696/cardiology.5.056
Troponin: Think Before Testing
Shakirat Ganiyu1,*, Fatimah Bello1, Danielle Stone2, Gregory Ruhnke3, James Stone2
- 1Department of Internal Medicine, The University of Texas Rio Grande Valley Knapp Medical Centre, Weslaco Texas, United States
- 2Department of Cardiology, University of Texas Health Science System, San Antonio, Texas, United States
- 3Department of Internal Medicine, The University of Chicago, Illinois, Chicago, United States
Corresponding Author
Shakirat Ganiyu, Shakirat.ganiyu@utrgv.edu
Received Date: May 11, 2024
Accepted Date: June 10, 2024
Ganiyu S, Bello F, Stone D, Ruhnke G, Stone J. Troponin: Think Before Testing. J Clin Cardiol. 2024;5(2):65-72.
Copyright: © 2024 Ganiyu S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
This is a high-value care-based quality improvement project that was carried out to decrease inappropriate troponin testing in the emergency department (ED) of a tertiary health institution in the United States with the goal of promoting evidence-based practices, minimizing waste, and enhancing the quality of care.
Keywords
High sensitivity troponin, Myocardial infarction, Myocardial injury, Myocardial ischemia
Recommended Articles
Diagnostic Value of Lung Ultrasonography in Comparison with Killip Classes after Angiography in Acute Myocardial Infarction: A Study from Iran
Acute myocardial infarction (AMI) with heart failure (HF), is the main cause of increased mortality. Early risk stratification by Killip classification is essential for its management. Today, non-invasive diagnostic methods such as lung ultrasound (LUS) are on the rise due to their ability to provide valuable insights without invasive methods. In this study we aimed to evaluate diagnostic value of LUS in comparison with Killip classes after angiography in AMI patients.
Immunomodulatory Effects of Cell Therapy after Myocardial Infarction
Myocardial infarction (MI) due to coronary artery stenosis compromises vascular endothelial integrity and increases vascular permeability. Concurrently, ensuing myocardial tissue death and necrosis results in the release of danger associated molecular patterns (DAMPs), cytokines, chemokines, bioactive lipids, as well as activation of the complement cascade.
COVID Pneumonia, Non-ST Elevation Myocardial Infarction, QRS Fragmentation, and Electrocardiographic Wavy Triple or Yasser's Sign in Hodgkin Lymphoma-Prognostic Influence and Serious Outcome
The COVID-19 virus with severe acute respiratory syndrome (SARS) has a remarkable effect on morbidity and mortality. Non-ST elevation myocardial infarction (NSTEMI) is a category of acute coronary syndrome (ACS) that may represent a primary cardiac manifestation of COVID-19 disease. The QRS-complex fragmentation had been considered a hallmark of structural heart disease. Wavy triple, an electrocardiographic sign (Yasser’s sign) is a new specific diagnostic sign and therapeutic guide for hypocalcemia.
Use of Sodium-Glucose Co-transporter-2 Inhibitors after Acute Myocardial Infarction
Whether sodium-glucose co-transporters-2 (SGLT2) inhibitors have beneficial effects on cardiovascular (CV) events and mortality if given within few days from acute myocardial infarction (AMI) is unknown. The DAPA-MI trial (n= 4,107) is the only available study designed to evaluate the impact of administration of dapagliflozin on CV outcomes and mortality if started within 10 days from occurrence of an AMI.